Substitute for form 1449A-B/PTO	Complete if Known		
77	Application Number	09/724,869	
' INFORMATION DISCLOSURE	Filing Date	November 28, 2000	
STATEMENT BY APPLICANT	First Named Inventor	Juha Punnonen, et al.	
	Group Art Unit	1639	
	Examiner Name	Teresa D. Wessendorf	
, (use as many sheets as necessary)	Attorney Docket Number	0155.130US	

		U.S. Patent Do	cument	Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,	
Examiner Initials	Cite No.	Number	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal	
tow	1	5,718,883		Harlan et al.	02-17-1998		
٠,١	2	5,738,852		Robinson et al.	04-14-1998	RECE	1
	3	5,858,776		Ostrand-Rosenberg et al.	01-12-1999	I I I LOLI	VL
	4	5,861,310		Freeman et al.	01-19-1999		
4	5	6,071,716		Freeman et al.	06-06-2000	MAY 0 2	200
<u> </u>	6	6,084,067		Freeman et al.	07-04-2000	1 02	kuu
1	7	6,149,905		Ostrand-Rosenberg et al.	11-21-2000	YECH CENTER 1	

	FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Office	Foreign Patent Docum	ent Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т	
taw	8	wo	94/24267		Robinson, William S.	10-27-1994			
TOW	9	wo	95/23859		Brigham & Women's Hospital; Dana-Farber Cancer Institute	09-08-1995			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Cite Initials No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).	Т		
Ta) 10		Fargeas, C.A., et al., "Identification of Residues in the V Domain of CD80 (B7-1) Implicated in Functional Interactions with CD28 and CTLA-4," Journal of Experimental Medicine 182(3):667-675 (1995)			
11		Freeman, G.J. et al., "Cloning of B7-2: A CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation," Science 262:909-911 (1993)			
7.	12	Guo, Y., et al., "Mutational Analysis and an Alternatively Spliced Product of B7 Defines Its CD28/CTLA-4 binding Site on Immunoglobulin C-like Domain," Journal of Experimental Medicine 181(4):1345-1355 (1995)			
0	13	He, X-S. et al., "Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen," Proc. Natl. Acad. Sci. USA 93:7274-7278 (1996)			
·	14	Kim, J.J. et al., "Engineering DNA Vaccines via Co-delivery of Co-Stimulatory Molecule Genes," Vaccine 16(19):1828-1835 (1998)			
0	15	Kuchroo, V.K. et al.," B7-1 and B7-2 Costimulatory Molecules Activate Differentially the Th1/Th2 Developmental Pathways: Application to Autoimmune Disease Therapy," Cell 80:707-718 (1995)			
a	16	Metzler, W., et al., "Solution Structure of Human CTLA-4 and Delineation of a CD80/CD86 Binding Site Conserved in CD28," Nature Structural Biology 4(7):527-531 (July 1997)			
17 Parsons, K.R., et al., "Cloning of Cattle CD80," Immunogenetics 49(3):231-234 (1999)		Parsons, K.R., et al., "Cloning of Cattle CD80," Immunogenetics 49(3):231-234 (1999)			

Examiner Signature	7. Wennedy	Date Considered	0/16	163
	11			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Complete if Known Substitute for form 1449A-B/PTO **Application Number** 09/724,869 November 28, 2000 Filing Date INFORMATION DISCLOSURE First Named Inventor Juha Punnonen, et al. STATEMENT BY APPLICANT **Group Art Unit** 1639 **Examiner Name** Teresa D. Wessendorf (use as many sheets as necessary) 0155.130US

Attorney Docket Number

thw	18	Peach, R.J., et al., "Both Extracellular Immunoglobulin-like Domains of CD80 Contain Residues Critical for Binding T Cell Surface Receptors CTLA-4 and CD28," Journal of Biological Chemistry 270(36):21181-21187 (1995)
	19	Rennert, P. et al., "The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion," International Immunology 9(6):805-813 (1997)
V	20	Wu, Y., "CTLA-4-B7 Interaction is Sufficient to Costimulate T Cell Clonal Expansion," J. Exp. Med. 185(7):1327-1335 (1997)

Examiner Signature 1. Williams	Date Considered	6/16/03

BACEN Complete if Known Substitute for form 1449A-B/PTO **Application Number** 09/724,869 Filing Date INFORMATION DISCLOSURE November 28, 2000 STATEMENT BY APPLICANT First Named Inventor Juha Punnonen **Group Art Unit** 1827-1639 **Examiner Name** <del>Unassigned</del> (use as many sheets as necessary) **Attorney Docket Number** 02-030310US **Date Submitted** May 21, 2002

	(una no many abasta na nacasana)		Examiner Name	( <del>Onussi</del> gned /	· Welley		
(use as many sheets as necessary)				Attorney Docket Number	02-030310US	. 0	
				Date Submitted May 21, 2002			_/
						ell only	7.7
	r			S. PATENT DOCUMENTS		2	vu
Examiner Initials	Cite No.	U.S. Patent Do Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal	) } }
TRW	1	5,252,714		Harris et al.	10-12-1993	1	8/2
;	2	5,264,563		Huse	11-23-1993	1	· //
<u> </u>	3	5,338,665		Schatz Et al	08-16-1994		
	4	5,348,867	•	Georgiou et al.	09-20-1994	DECENIED.	
1	5	5,470,725		Borriss et al.	11-28-1995	KEUEIVED	
	6	5,512,463		Georgiou et al.	09-20-1994	JUN 1. 0 2002	
	7	5,514,588		Varadaraj	05-07-1996	TECH CENTER 1600/290	)()
	8	5,523,388		Huse	06-04-1996	LECH CENTER TOUGHTOO	
\	9	5,571,698		Ladner et al.	11-05-1996		
,	10	5,589,466		Felgner et al.	12-31-1996	COPY OF PAPERS	
<u> </u>	11	5,593,972		Weiner et al.	01-14-1997	ORIGINALLY FILED	
Vatrie	12	5,605,793		Stemmer et al	02-25-1997		-
+2W	13	5,691,170		Gritz et al.	11-25-1997		
<u>.</u>	14	5,698,426		Huse	12-16-1997		
<u> </u>	15	5,703,057		Johnston et al.	12-30-1997		
ι	16	5,723,323		Kauffman et al.	03-03-1998		
	17	5,763,192		Kauffman et al.	06-09-1998		
	18	5,763,239		Short et al.	06-09-1998		
	19	5,770,434		Huse	06-23-1998		
1	20	5,783,386		Jacobs, Jr. et al.	07-21-1998		
	21	5,789,228		Lam et al.	08-04-1998		
₩	22	5,808,022		Huse	09-15-1998		
Hot.	23	5,811,238		Stemmer et al.	09-22-1998		

Examiner
Signature

T. Wundy

Considered

6/13/83

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number

O9/724,869

Figh g Date
November 28, 2000

First Named Inventor

Group Art Unit
1627

Examiner Name
Unassigned

Attorney Docket Number

O2-030310US

Date Submitted

May 21, 2002

The	24	5,814,473	Warren et al.	09-29-1998		
1	25	5,814,476	Kauffman et al.	09-29-1998		
	26	5,817,483	Kauffman et al.	10-06-1998		
-	27	5,824,469	Horwitz et al.	10-20-1998		
	28	5,824,514	Kauffman et al.	10-20-1998	DECEN/E	n
	29	5,830,696	Short	11-03-1998	RECEIVE	
	30	5,830,721	Stemmer et al.	11-03-1998	JUN 1 0 2002	
	31	5,834,252.	Stemmer et al	11-10-1998	TECH CENTER 1600	
	32	5,837,458	Minshull et al.	11-17-1998	1FCH CEIMIEU 1004	1200
	33	5,862,514	Kauffman et al.	10-20-1998		
	34	5,866,344	Georgiou	02-02-1999	COPY OF PAPER	
	35	5,866,363	Pieczenik	02-02-1999	ORIGINALLY FILE	ט
	36	5,871,974	Huse	02-16-1999		
,	37	5,876,997	Kretz	03-02-1999		
	38	5,882,883	Egel-Mitani et al.	03-16-1999		
W	39	5,925,749	Mathur, et al.	07-20-1999		
Dot	40	5,928,905.	Stemmer et al	07-27-1999		
onfile	41	5,939,250	Short	08-17-1999		
Han	42	5,939,300	Robertson, et al.	08-17-1999		
Ĭ/	43	5,942,430	Robertson, et al.	08-24-1999		
1	44	5,948,666	Callen, et al.	09-07-1999		
	45	5,955,358	Huse	09-21-1999		
You su	46	5,958,672	Short	09-28-1999		
tan	47	5,958,751	Murphy, et al.	09-28-1999		
the	48	5,962,258	Mathur, et al.	10-05-1999		

Examiner	_ , .	Date	
Signature	J. Wissey	7 Considered	6/13/65

Substitute for form 1449A-B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

l Č		omplete if Known	
	Application Number	09/724,869	
?	Anting Date	November 28, 2000	
	First Named Inventor	Juha Punnonen	
	Group Art Unit	1627	
	Examiner Name	Unassigned	
	Attorney Docket Number	02-030310US	
	Date Submitted	May 21, 2002	

Withi	49	5,965,408	Short	10-12-1999	31-30 <sup>-1</sup> 0-10-10-10-10-10-10-10-10-10-10-10-10-10
This	50	5,962,283	Warren et al.	10-05-1999	
ř	51	5,976,862	Kauffman et al.	11-02-1999	
1	52	5,985,285	Titball et al.	11-16-1999	RECEIVED
_	53	5,985,646	Murphy, et al.	11-16-1999	HEO. 2002
J	54	5,989,553	Johnston, et al.	11-23-1999	JUN 1 0 2002
North	55	6,001,574	Short et al.	12-14-1999	TECH CENTER 1600/2900
1	56	6,004,788	Short	12-21-1999	1EOU OF
V	57	6,030,779	Short	02-29-2000	
-12hw	58	6,043,030	Beach et al.	03-28-2000	COPY OF PAPERS
witer	59	6,054,267	Short	04-25-2000	ORIGINALLY FILED
TRU	60	6,054,312	Lacocca et al.	04-25-2000	
J. J. C.	61	6,057,103	Short	12-21-1999	
Tour	62	6,087,341	Khavari et al.	07-11-2000	
1 1	62A	6,096,548	Stemmer	08-01-2000	
Con	63	6,117,679	Stemmer	9-12-2000	
infu	<sup>1</sup> 64	6,132,970	Stemmer	10-17-2000	
HOU	65	6,153,410	Arnold et al.	11-28-2000	
1	66	6,156,511	Schatz et al.	12-05-2000	
1	67	6,159,687	Vind	12-12-2000	
)	68	6,159,688	Borchert et al.	12-12-2000	
1/	69	6,165,718	Borchert et al.	12-26-2000	
NUT	70	6,165,793	Short	12-26-2000	
$\sim$	71	6,168,919	Short	01-02-2001	
file	72	6,171,820	Short et al.	01-09-2001	

Examiner
Signature

Date
Considered

Considered

THAT TRACE INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

L Co	omplete if Known	
App@cation Number	09/724,869	
Filing Date	November 28, 2000	
First Named Inventor	Juha Punnonen	
Group Art Unit	1627	
Examiner Name	Unassigned	
Attorney Docket Number	02-030310US	
Date Submitted	May 21, 2002	

Not	73	6,174,673	Short et al.	01-16-2001	
m	74	6,177,263	Arnold et al.	01-23-2001	DECEIVED
he	75	6,180,406	Stemmer et al.	01-30-2001	RL 0 2002
The Trew	76	6,194,183	Markvardsen et al.	02-27-2001	JUNT
1	77	6,238,884	Short et al.	05-29-2001	TECH CENTER 1600 2900
	78	6,251,674	Tobin et al.	06-26-2001	15011
	79	6,261,561	Stewart, Jr. et al.	07-17-2001	
	80	6,287,861	Stemmer et al.	09-11-2001	

				FOREIGI	N PATENT DOCUMEN	TS	•
Exami ner Initials	Cite No.	Office	Foreign Patent Docu Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages T or Relevant Figures Appear
TOW	81	EP	0 125 228	A1	President and Fellows of Harvard College	06-15-1988	COPY OF PAPERS ORIGINALLY FILED
i	82	EP	0554809	B1	Ixsys, Inc.	12-16-1998	
	83	EP	0563296	B1	Ixsys, Inc.	03-17-1999	
	84	EP	0 725081	A1	Kyowa Hakko Kogyo Co., Ltd.	08-07-1996	
	85	EP	0 752008	B2	Maxygen, Inc.	02-17-1995	
	86	EP	0876509	B1	Maxygen, Inc.	09-19-2001	
	87	EP	0911396	A2	Stemmer	04-28-1999	
	88	EP	0911396	A3	Stemmer et al.	05-06-1999	
	89	EP	0934999	A1	Stemmer et al.	08-11-1999	
	90	wo	90/14424		Scripps Clinic and Research	11-29-1990	

		q	
Examiner Signature	T. Whendy	Date Considered	4/13/63
		<del></del>	

5 2002

Complete if Known Substitute for form 1449A-B/PTO **Application Number** 09/724,869 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT First Named Inventor Juha Punnonen **Group Art Unit** 1627 **Examiner Name** Unassigned (use as many sheets as necessary) Attorney Docket Number 02-030310US May 21, 2002 **Date Submitted** 

							10 tos
					Foundation		100
NW	91	wo	90/14443		Huse	11-29-1990	CENTERIBUS
1	92	WO	91/07979		Center for Innovative Technology	06-13-1991	TECH CENTER 1800
7	93	wo	92/03461		lxsys, Inc.	03-05-1992	
1	94	wo	92/06176		Ixsys, Inc.	04-16-1992	
	95	wo	92/06204		Ixsys, Inc.	04-16-1992	
1	96	wo	92/11272		Ixsys, Inc	07-09-1992	
ı	97	wo	93/06214		The United States of America	04-01-1993	
1	98	wo	93/10214		Georgiou	05-27-1993	
	99	wo	94/06421		The University of Tennessee Research	03-31-1994	COPY OF PAPERS ORIGINALLY FILED
	100	wo	94/06911		Board of Regents, The University of Texas System	03-31-1994	
	101	wo	94/11496		Ixsys, Inc.	05-26-1994	
	102	wo	94/23738	A1	Medisorb Technologies International L.P.	10-27-1994	
, (	103	wo	94/25608		Baylor College of Medicine	11-10-1994	,
4	104	wo	94/26787	A1	The Boead of Trustees of the Leland Stanford Junior University	11-24-1994	
Porni	105ء	wo	95/22625		Stemmer et al.	08-24-1995	
town	106	wo	95/16027	A1	Borrebaeck	06-15-1995	
du	106	wo	95/16027	A1	Borrebaeck	06-15-1995	

Examiner Signature	T. Vissely	Date Considered	6/13/23
<u> </u>		<del> </del>	1

IRE TRADE Filing Date
First Name Complete if Known Substitute for form 1449A-B/PTO plication Number 09/724,869 INFORMATION DISCLOSURE November 28, 2000 STATEMENT BY APPLICANT First Named Inventor Juha Punnonen 1627 **Group Art Unit** Unassigned **Examiner Name** (use as many sheets as necessary) 02-030310US **Attorney Docket Number Date Submitted** May 21, 2002

							1111 1 0 500	سعير
TOW	107	wo	95/26718		Apollon, Inc.	10-12-1995	-UTER 16	00
1	108	wo	96/11279	A1	US Department of Health and Human Services	04-18-1996	TECH CENTER 16	
1.	109	wo	96/13250	A1	Amgem, Inc.	05-09-1996		
	110	wo	96/23882		The Rockefeller University	08-08-1996		
L	111	wo	96/31613		Board of Regents	10-10-1996		
to Fe	112	wo	96/33207		Glaxo Group Limited	10-24-1996		
100	113	wo	96/37624		MG-PMC, L.L.C.	11-28-1996		
f	114	wo	97/04077		Recombinant Biocatalysis, Inc.	02-06-1997		
	115	wo	97/07128	A1	Duke University	02-27-1997		
1	116	wo	97/07205		Okkels	02-27-1997		
	117	wo	97/11605	A1	University of Pittsburg of the Commonwealth System of Higher Education	04-03-1997	COPY OF PAPERS ORIGINALLY FILED	
19 Th	118	wo	97/20078		Stemmer et al.	06-05-1997		
taw	119	wo	97/25410		Borchert et al	07-17-1997		
Din	120	wo	97/32987	A1	University of Toronto	09-12-1997		
4	121	wo	97/35957	A1	Stemmer	10-02-1997		
1	122	wo	97/35966		Maxygen Inc.	10-07-1997		
	123	wo	97/44361		Lam et al.	11-27-1997		
	124	wo	97/48416		Mathur et al.	12-24-1997		
	125	wo	97/48717		Short et al.	12-24-1997		
V	126	wo	97/48794		Murphy et al.	12-24-1997		

		į į	
Examiner Signature	T. Wenned	Date Considered	6/13/03

Complete if Known Substitute for form 1449A-B/PTO pplication Number 09/724,869 INFORMATION DISCLOSURE Filing Date November 28, 2000 Juha Punnonen STATEMENT BY APPLICANT First Named Inventor Group Art Unit 1627 Unassigned **Examiner Name** (use as many sheets as necessary) 02-030310US **Attorney Docket Number** May 21, 2002 **Date Submitted** 

						-CEIVE
Then	127	wo	98/00526	Robertson et al.	01-08-1998	BECEIVED
1	128	wo	98/01581	Short	01-15-1998	JUN ! 0 20 TECH CENTER 16001
1	129	wo	98/05764	Novo Nordisk	02-12-1998	CENTER 18001
1	130	wo	98/05765	Novo Nordisk	02-12-1998	TECHOLI
	131	wo	98/13485	Stemmer et al.	04-02-1998	
	132	wo	98/13487	Stemmer et al.	04-02-1998	
1	133	wo	98/24799	Bylina	06-11-1998	
	134	wo	98/27230	Patten et al.	06-25-1998	
	135	wo	98/28416	Bjornvad et al.	07-02-1998	
1	136	wo	98/31816	Regents of the University of Minnesota	07-23-1998	COPY OF PAPERS ORIGINALLY FILED
1	137	wo	98/31837	Delcardayre et al.	07-23-1998	
	138	wo	98/36080	Affholter et al.	08-20-1998	
1.	139	wo	98/41622	Borchert et al.	09-24-1998	
	140	wo	98/41623	Borchert et al.	09-24-1998	
V	141	wo	98/41653	Vind et al.	09-24-1998	
10 gri	-142	wo	98/42727	SRI International	10-01-1998	
the	143	wo	98/42832	Arnold et al.	10-01-1998	
į	144	wo	98/45444	The Regents of the University of California	10-15-1998	
•	145	wo	98/48034	Neiboer et al.	10-29-1998	
	146	wo	98/49286	Board of Regents, The University of Texas System	11-05-1998	
V	147	wo	98/58085	Short et al.	12-23-1998	

	ן	}
Examiner	Date	
Signature	Considered	

JUN 0 5 2002 BAPPIlorati

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	E C	omplete if Known	
	Apple ation Number	09/724,869	
n	- Fing Date	November 28, 2000	
_	First Named Inventor	Juha Punnonen	
	Group Art Unit	1627	
	Examiner Name	Unassigned	
	Attorney Docket Number	02-030310US	
	Date Submitted	May 21, 2002	

		1	00/07027		1	
jan	148	wo	99/07837	Callen	02-18-1999	DECEIVE
1	149	wo	99/08539	Kretz	02-25-1999	HEO 2002
4	150	wo	99/10472	Short	03-04-1999	RECEIVED
	151	wo	99/10539	Short	03-04-1999	TECH CENTER 1600
,	152	wo	99/19506	ixsys, inc.	04-22-1999	1ECH OF.
Π.	154	wo	99/19518	Short	04-22-1999	
,	155	wo	99/21979	Apt et al.	05-06-1999	
	156	wo	99/23107	Stemmer et al.	05-14-1999	
	157	wo	99/23236	Diversa Corp. et al.	05-14-1999	
	158	wo	99/29902	Arnold et al.	06-17-1999	
	159	wo	99/41366	The Board of Trustees of the Leland Stanford Junior University	08-19-1999	COPY OF PAPERS ORIGINALLY FILED
1.1	160	wo	99/41368	Maxygen, Inc.	08-19-1999	
	161	wo	99/41369	Maxygen, Inc.	08-19-1999	
	162	wo	99/41383	Maxygen, Inc.	08-19-1999	
	163	wo	99/41402	Maxygen, Inc.	08-19-1999	
	164	wo	99/45154	Short et al.	09-10-1999	
	165	wo	99/57128	Stemmer et al.	11-11-1999	
	166	wo	99/65927	Maxygen, Inc,	12-23-1999	
	167	wo	00/18778	Phylos, Inc.	04-06-2000	
	168	wo	00/42560	Selifonov et al.	07-20-2000	
-	169	wo	00/42561	Crameri et al.	07-20-2000	
	170	wo	00/46344	Diversa Corrporation	08-10-2000	
Á	171	wo	00/53744	Short et al.	09-14-2000	

			9
Examiner		Date	
Signature	T. Wendy	Considered	6/13/13
			· / /

Substitute for form 1449A-B/PTO Complete if Known Macina **Application Number** 09/724,869 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT First Named Inventor Juha Punnonen **Group Art Unit** 1627 **Examiner Name** Unassigned (use as many sheets as necessary) **Attorney Docket Number** 02-030310US **Date Submitted** May 21, 2002

172	wo	00/58517	Short et al.	10-05-2000	JUN 1900/2900
173	wo	00/16984	Maxygen, Inc	03-30-2000	TECH CENTER 1800/2900
174	wo	01/00234	Maxygen, Inc	01-04-2001	
					COPY OF PAPERS ORIGINALLY FILED

	,	OTHER PRIOR ART. MON PATENT LITERATURE PROMINENTS	т-
		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	╀
Exami ner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
thw	175	Affholter et al. (1998) "Directed evolution of proteins and pathways by DNA shuffling." Book of Adstracts, 216th ACS National Meeting, Boston, August 23-27, BIOT-042	
	176	Agren et al. (1997) "Genetically Engineered Nontoxic Vaccine Adjuvant That Combines B Cell Targeting with Immunomodulation by Cholera Toxin A1 Subunit." J. Immunol 158:3936	
	177	Ahmed (1995) J Bacteriology 177(14):3904-3910	Ī
	178	Ahn et al. (1996) "Human cytomegalovirus inhibits antigen presentation by a sequential multistep process." <i>Proc. Natl. Acad, Sci USA</i> 93:10990	
-	179	Aizaki et al. (1998) "Full-Length Complementary DNA of Hepatitus C Virus Genome From an Infectious Blood Sample." Hepatology 27:621-627 (1998)	
	180	Aldovini & Young (1991) "Humoral and cell-mediated immune response to live recombinant BCG-HIV vaccines." Nature 351:479-482	I
	181	Ambriovic, A. et al. (1997) "Efficacy of Replication-Defective Adenovirus-Vectored Vaccines: Protection Following Intramuscular Injection Is Linked to Promoter Efficiency in Muscle Representative Cells" Virology 238:, 327-335	
	182	Appel and Harris (1998) "Antiboby titers in domestic ferret fills and kits to canine distemper virus vaccines." <i>JAVMA</i> 193:332-333	1
-	183	Atkins et al. (1996) "Manipulation of the Semliki Forest Virus Genome and Its Potential for Vaccine Construction." <i>Mol Biotechnol</i> 5:33-38	1
1	184	Attridge et al. (1997) "Oral delivery of foreign antigens by attenuated Salmonella: consequences of prior exposure to the vector strain." Vaccine 15(2): 155-162	Ī
V	185	Axon (1998) "Treatment of Helicobacter pylori: future therapeutic and prophylactic perspectives." Gut 43(1):S70-3	1
Spri	<sub>2</sub> 186	Baba et al., "Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-directed CC Chemokine LARC," The J. of Biolog. Chem. 272 (23): 14893-14898 (1997)	
tow	187	Barry et al. (1994) "Production of monoclonal antibodies by genetic immunization." Short Technical Reports in Biotechniques 16(4):616	I
-nu	188	Barry et al. (1995) "Protection against nycoplasma infection using expression-library immunization."  Nature 377:632	

Examiner		Date	(./ /
Signature	T. Winny	Considered	613/23
<u> </u>			**************************************

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application.

Application.

First Name Complete if Known Application Number 09/724,869 November 28, 2000 First Named Inventor Juha Punnonen Group Art Unit 1627 **Examiner Name** Unassigned 02-030310US **Attorney Docket Number Date Submitted** May 21, 2002

pin	189	Bass et al. (1990) "Hormone Phage: An Enrichment Method for Variant Proteins With Altered Binding Properties." <i>Proteins: Structures, Function and Genetice</i> 8:309-314
wat	190	Beattle et al. (1990) "Cloning and characterization of T-cell-reactive protein anigens from Listeria monocytogenes." Infection and Immunity 58(9):2792-2803
fri	191	Beck et al., "DNA Sequence Analysis of 66 kb of the Human MHC Class II Region Encoding a Cluster of Genes for Antigen Processing," J. Mol. Biol. 228:433-441 (1992)
Tin	192	<b>Behrens et al.</b> (1996) "Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus." <i>EMBO J.</i> 15:12-22
, (·	193	<b>Benham et al.</b> (1997) *Proteasome activity limits the assembly f HMC class 1 molecules after IFN-gamma stimulation." <i>J. Immol</i> 159(2):5896-5904
	194	Berkhout et al. (1999) "Genetic Instability of Live, Attenuated Human Immunodeficiency Virus Type I Vaccine Strains." <i>J. Virology</i> 73(2):1138-1145
	195	Bernard et al. (1994) "Transcriptional Control and Cell Type Specificity of HPV Gene Expression." Arch Dermatol 130:210
	196	<b>Bhatnagar et al.</b> (1982) "Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the a determinant." <i>Proc Nat'l Acad Sci USA</i> 79:4400-4404
. 1	197	Bielefeldt-Ohmann, H. et al., "Analysis of a recombinant dengue-2 virus-dengue-3 virus hybrid envelope protein expressed in a secretory baculovirus system," J. Gen. Virol. 78:2723-2733 (1997)
Note I	198	Blachere et al., "Heat Shock Protein-Peptide Complexes, Reconstituted In Vitro, Elicit Peptide-specific Cytotoxic T Lymphyocyte Response and Tumor Immunity," J. Exp. Med. 186:1315-22 (1997
tow	199	Blanchard et al. (1998) "Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins " J. Gen. Virol 79:1159-1167
1	200	Blaser (1998) "Helicobacter pylori and gastric disease." BMJ 316:1507-1510
	201	<b>Bloom et al.</b> (1993) Characterization of Chimeric Full-Length Molecular Clones of Aleutian Mink Disease Parvovirus (ADV) * J. Virol 67(10):5976-5988
¥	202	<b>Bolhuis</b> (1995) <i>J. Biological Chamistry</i> 270(3):26092-26098
Wat w	203	Botstein and Shortle, "Strategies and Applications of in Vitro Mutagenesis," Science 229:1193-1201 (1985)
-15U	204	Boursnell et al. (1997) "A Genetically Inactivated Herpes Simplex Virus Type 2 (Hsv-2) Vaccine Provides Effective Protection against Primary & Recurrent HSV-2 Disease." J. Infect. Dis 175:16-25
-	205	Bray et al. (1989) "Mice Immunized with Recombinant Vaccinia Virus Expressing Dengus Virus Encepha;it is." J. Virol 63:2853-2856
	206	Bridgen and Elliot (1996) "Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNA's." <i>Proc. Nat'l Acad. Sci USA</i> 93:15400-15404
	207	Brocke et al. (1996) "Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein." Nature 379:343-346
	208	Brubaker (1991) "The V Antigen of Yersiniae: An Overview." Current Investigations of the Microbiology of Yersinae 12:127-133
	209	Burger et al. (1995) Proc. of thr Amer Assoc. for Cancer Research 36:522 Abst #3108
1	210	Burke et al. (1999) "Formulation, Stability and Delivery of Live Attenuated Vaccines for Human Use."  Crit. Rev. Ther Drig. Carrier Syst 16:1-83
		q q
		1

May 21, 2002

TRACE Application Number Substitute for form 1449A-B/PTO Complete if Known 09/724,869 November 28, 2000 INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor Juha Punnonen Group Art Unit 1627 **Examiner Name** Unassigned (use as many sheets as necessary) 02-030310US **Attorney Docket Number** 

**Date Submitted** 

		Burton (1995) "Phage Display." Immunotechnology 1(2):87-94		
- HOW	211			
+021	212	Carroll and Moss (1997) "Host range and Cytopathogenicity of the Highly Attenuated MVA Strain of Vaccinia Virus" Virology 238:198-211		
Net	213	Carter et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors," Nucl. Acids Res. 13:4431-4443 (1985)		
من	214	154:382-403 (1987)	nods in Enzymol.	
Rile	215			
fair	216	Biotechnol Appl. Biochem 29:-141-150	immune response."	
pdin	217	Cathomen et al. (1998) "A matrix-less measles virus is infectious and extensive ce consequences for propagation in the brain." <i>EMBO J.</i> 17(14):3899-3908	Il fusion:	
J. The	218	Chang, C., et al. (1999) "Evolution of a cytokine using DNA family shuffling." Natur 17:793-797.	e Biotechnology	
-fall	219	Observation ID - Later T Oall Observation of the Control Telegraphic Compression of	Autoimmune	
WOY,	220	Chen et al., "Discontinuous epitopes of hepatitis B surface antigen derived from a feetide library." Proc. Nat'l. Acad. Sci. USA 93:1997-2001 (1996)		
120	221	Ohio at at (4000) #Functions and Deculation of the Human Miltidaus Posistance C	ene." Adv. Cancer	
12:	222	Ot to the state of	Survival In Vivo."	
NOT	223	OLD TO THE WORLD THE STATE OF T		
fal	224	Of the Automotive State of the	sters from Challenge	
	225	Olaska an et al. (4004) No vitus estantian from austain and pentide libraries " Trans	s Biotechnol 12(5):	
	226		and evolved	
	227	Only and the (4000) Har lefe stigned Malacular Claracters of an Universal Magazanhaga	ropic and Highly	
	228			
	229	Company (4004) III	e vassine." Cancer	
	230	Coppel et al. (1993) "idenification of a coda clone encoding a mature blood stage antigen of Plasmodium falciparum by immunization of mice with bacterial lysates." EMBO Journal 3)2):403-407		
	231	Cote et al. (1986) "Protection of Chimpanzees from Type B Hepatitis by Immunization with Woodchuck Hepatitis Virus Surface Antigen." <i>J. Virol</i> 60:895-901		
NEW	232	Courvalin et al. (1995) "Gene transfer from bacteria to mammalian cells." C.R. Ac	ad. Sci III 18:1207-	
7	Т			
Evan	inor	Date		
Exam		T. Windy Considered	6/1.	
Signature		T. Ward Considered 6/12/03		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

May 21, 2002

0 5 2002 H

Complete if Known Substitute for form 1449A-B/PTO 09/724,869 **Explication Number** INFORMATION DISCLOSURE Filing Date November 28, 20**0**0 STATEMENT BY APPLICANT First Named Inventor **Juha Punnonen Group Art Unit** 1627 Unassigned **Examiner Name** (use as many sheets as necessary) 02-030310US Attorney Docket Number

**Date Submitted** 

		1212
17th 2	233	Crabtree (1998) "Eradication of chronic Helicobacter pylori infection by therapeutic vaccination." <i>Gut</i> 43:7-8
King a	234	Craiu et al., "Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide," Proc. Nat'l. Acad. Sci. USA 94:10850-10855 (1997
1 "	235	Crameri & Stemmer (1993) "10(20)-fold aptamer library amplification without gel purification." Nucleic Acids Research 21(18): 4410
22/14	236	Crameri, A. et al., "Combinatorial Multiple Cassette Mutagenesis Creates All the Permutations of Mutant and Wild-Type Sequences," Biotechniques 18:194-195 (1995)
7 2	237	Crameri, A. et al., "Construction and evolution of antibody-phage libraries by DNA shuffling," Nature Medicine 2:100-103 (1996)
1 2	238	Crameri, A. et al., "DNA shuffling of a family of genes from diverse species accelerates directed evolution," Nature 391:288-291 (1998) (2-287-1PC & 2-251PC)
7 2	239	Crameri, A. et al., "Improved Green Fluorescent Protein by Molecular Evolution Using DNA Shuffling," Nature Biotechnology 14:315-319 (1996)
1 2	240	Crameri, A. et al., "Molecular evolution of an arsenate detoxification pathway by DNA shuffling," Nature Biotechnology 15:436-438 (1997)
<b>1</b> 2	241	Cresswell & Hughes, "Protein degradation: The ins and outs of of the matter," Curr. Biol. 7:R552-R555 (1997)
Meri 2	242	Cwirla et al. (1990) "Peptides on Phage: A vast library of peptides for identifying ligands." <i>Proc. Nat'l Acad Sci USA</i> 87:6378-6382
1 2	243	Davis et al (1995) "DNA-based immunization." <i>Molecular and Cell Biology of Human Gene Therapeutics</i> 5:368-387
9 2	245	<b>Davis et al.</b> (1989) "In vitro Synthesis of Infectious Venezuelar Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant." <i>Virology</i> 171:189-204
1	246	Davis et al. (1997) "DNA-Based immunization against hepatitis B surface antigen (HBsAg) in Normal and HBsAg-transgenic mice." <i>Vaccine</i> 15(8) 849-822
2	247	Deng et al. (1997) "Sustainable cutaneous gene delivery." Nature Biotechnol 15:1388-1391
	248	<b>Devlin et al.</b> (1990) "Random Peptide Libraries: A Source of Specific Protein Binding Molecules."  Science 249:404-406
20this	249	<b>Dieu et al.,</b> "Selective Recruitment of Immature and Mature Dendritic Cells by Distinct Chemokines Expressed in Different Anatomic Sites," J. Exp. Med. 188:373-386 (1998)
1/ 1	250	<b>DiMarco et al.</b> (1997) "Agnostic and antagonistic variants of ciliary neurothrophic Factor (CNTF) Reveal functional differences between mambrean-bound and soluble CNTF Alpha-receptors." <i>J Biol. Chem.</i> 272(37):23069-23075
1 2	251	<b>Donovan et al.</b> (1987) "Genes Encoding Spore Coat Polypeptides from Bacillus subtilis." J. Mol Biol 196:1-10
2	252	Drabkin et al. (1996) "Amber Suppression in Mammalian Cells Dependent upon Expression of an Escherichia coli Aminoacyl-tRNA Synthetase Gene." <i>Mol Cell. Biol.</i> 16(3):907-913
1/ 2	253	Dubols et al. (1998) "Immunization against Natural Helicobacter pylori Infection in Nonhuman Primates." <i>Infect. Immun.</i> 66:4340-4346

			9
Examiner		Date	
Signature	T. Wurd	Considered	4/11/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO
INFORMATION DISCLOSURE
PADE TO A PRI ICANT Complete if Known 09/724,869 Application Number November 28, 2000 Ming Date STATEMENT BY APPLICANT First Named Inventor Juha Punnonen 20<del>02 0 1 NUL</del> **Group Art Unit** 1627 **Examiner Name** Unassigned ECH CENTER 1600/2900 (use as many sheets as necessary) Attorney Docket Number 02-030310US **Date Submitted** May 21, 2002

4	254	Dunn (1996) "Phage display of proteins." Curr Opin Biotechnology 7(5):547-553		
1	255	<b>Eghtedarzadeh and Henikoff,</b> "Use of oligonucleotides to generate large deletions," Nucl. Acids Res. 14:5115 (1986)		
1	256	Engels and Ackermann (1996) "Pathogenesis of ruminant herpesvirus infections." Vet Microbiol 53:3-		
<b>í</b>	257	Felici, Franco et al., "Peptide and protein display on the surface of filamentous bacteriophage," Biotechnol. Annu. Rev. 1:149-83 (1995)		
(	258	Fields et al., "Crystal structure of a T-cell receptor B-chain complexed with a superantigen," Nature 384:188-192 (1996)		
,	259	Fox et al. (1996) "Anaerobic bacteria as a delivery system for cancer gene therapy: In vitro activation of 5-fluorocytosine by genetically engineered clostridia." Gene Ther 3:173-178		
•	260	Francisco, Joseph A. et al., "Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface," Proc. Nat'l. Acad. Sci. USA 90:10444-10448 (1993)		
	261	Frankel and Young (1998) "HIV-1 Fifteen Proteins and an RNA." Annu. Rev. Biochem 67:1-25		
7	262	Freeman et al., "B7-1 and B7-2 Do Not Deliver Identical Costimulatory Signals, Since B7-2 but Not B7-1 Preferentially Costimulates the Initial Production of IL-4," Immunity 2:523 (1995)		
•	263	Fritz et al. "Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro," Nucl. Acids Res. 16:6987-6999 (1988)		
?,	264	Fritz et al. "Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro," Nucl. Acids Res. 16:6987-6999 (1988)		
7	265	Gaczynska et al.,"Proteasome Subunits X and Y alter Peptidase Activities in Opposite Ways to the Interferon-γ-induced Subunits LMP2 and LMP7*,J. Biol. Chem. 271:17275-17280 (1996)		
•	266	Galler et al. (1997) "The Yellow fever 17D vaccine virus: molecular basis of viral attnuation and its use as an expression vector." <i>J. Med Biol. Res.</i> 30:157-168		
1	267	Galocha et al. (1997) "The Active Site of ICP47, a Herpes Simple Virus-encoded Inhibitor of the Major Histocompatibility Complex " J. Exp. Med 185:1565-1572		
١	268	Garnett and Grenfell (1992) "The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster." <i>Epidemiol. Infect</i> 108:513-528		
۸	269	Gates, C.M. et al., "Affinity Selective Isolation of Ligands from Peptide Libraries Through Display on a lac Repressor 'Headpiece Dimer™ J. Mol. Biol. 255:1-14 (1996)		
•	270	Geigenmuller et al. (1997) "Construction of a Genome-Length cDNA Clone for Human Astrovirus Serotype 1 and Synthesis of Infectious RNA Transcrips." <i>J. Virol</i> 71:1713-1717		
r	271	Goldman et al. (1999) Molecular Cloning and Expression of Major Structural Protein" J. Virol. 73:4465-4469		
,	272	Gritsun et al. (1998) "Development and analysis of a tick-bone encephalitis virus infectious clone using a novel and rapid strategy." J Virol. Methods 76:109-120		
9	273	Groettrup et al. "The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome," Proc. Nat'l. Acad. Sci. USA 94:8970-8975 (1997)		
7	274	Groettrup et al., "A third interferon –γ-induced subunit exchange in the 20S proteasome," Eur. J. Immunol. 26:863-869 (1997)		

	[	
Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUN 0 5 2002 W

Substitute for form 1449A-B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	(9 C	omplete if Known	
	Asplication Number	09/724,869 RECEIVE	)
Š	Filing Date	November 28, 2000	,
	First Named Inventor	Juha Punnonen JUN 1 0 2002	
	Group Art Unit	1627 JOIN ( 0 2002	
	Examiner Name	Unassigned TEOLLOCATED 4000/00	^^
	Attorney Docket Number	02-030310US TECH CENTER 1600/29	W
	Date Submitted	May 21, 2002	

r	<del></del>	LOwer And TA COA. The Hard in this coal and the Coal and	
MAT	275	Groux et al.,"A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis," Nature 389:737 (1997)	
hu 276		Grundstrom et al., "Oligonucleotide-directed mutagenesis by microscale 'shot-gun' gene synthesis," "Nucleic Acids Res. 13:3305-3316 (1985)	
fre	277	Gualano et al. (1998) "Identification of a major determinant of mouse neurovirulence of dengue virus typw 2 using stably cloned genomic-length cDNA." <i>J. Gen. Virol.</i> 79:437-466	
	278	Guo et al. (1998) "Susceptibility to recombination rearrangements of a chimeric plum pox potyvirus genome after insertion of a foreign gene." Virus Res 57:183-195	
1	279	Halminen et al. (1997) "Expression of MXA Protein in Blood Lymphocytes Discriminates between Viral and Bacterial Infections in Febrile Children." <i>Pediatric Research</i> 41:647-650	
	280	Han, Xiaoliang et al., "Ligand-directed retroviral targeting of human breast cancer cells," Proc. Natl. Acad. Sci USA 92:9747-9751 (1995)	
1	281	Hanes, Jozef and Andreas Pluckthun., "In vitro selection and evolution of functional proteins by using ribosome display," Proc. Nat'l. Acad. Sci. USA 94(10):4937-42 (1997)	
A	282	Haq et al. (1995) *Oral Immunization with a Recombinant Bacterial Antigen Produced in Transgenic Plants.* Science 268:714-716	
t	283	Haralamblev (1967) "Immunogenicity Studies on a Inactivated IBR Vaccine Administered Into the Nasal Mucosa." Acta Vet Acad Sci Hung 26:215-217	
· ·	284	Harrington et al. (1992) "An outbreak of Respiratory Syncytial Virus in a Bone Marrow Transplant Center." J. Infect Dis. 165:987-993	
r.	285	HCJ Ertl et al., (1996) "Genetic Immunization" Viral Immunization Vol. 9, No. 1, pp. 1-9.	
(	286	He et al., "Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites," Nucl. Acids Res. 25(24):5132-4 (1997)	
•	287	<b>He et al.</b> (1998) "The Paramyxovirus SV5 Small Hydrobhobic (SH) Protein Is Not Essential for Virus Growth in Tissue Culture Cells." <i>Virology</i> 250:30-40	
,	288	Hedstrom et al. (1994) "Prospects and strategies for development of DNA vaccines against malaria."  59th Forum in Immunology 476-482	
	289	Hensel and Lubitz (1997) Vaccination by Aerosols: Modulation of Clearance Mechanism in the Lung."  Behring. Inst. Mitt. 98:212-219	
	290	Hilgers et al. (1990) "Caco-2 Cell Monolayers as a Model for Drug Transport Across the Intestional Mucosa." Pharmaceutical Res. 7(9):902-910	
,	291	Hill et al., "Phage presentation," Mol Microbiol 20(4):685-92 (1996)	
	292	Hoffman and Banerjee (1997) "An Infectious Clone of Human Parainfluenza Virus Type 3." J Virol. 71:4272-4277	
,	293	Hohol et al. (1996) "Three-year Open Protocol Continuation Study of Oral Tolerization with Myelin Antigens in Multiple Sclerosis and Design of a phase III Pivotal Trial." Ann. N.Y. Acad Sci. 778:243-250	
	294	Holzmann, H. et al., "Molecular epidemiology of tick-borne encephalitis virus: cross-protection between European and Far Eastern subtypes," Vaccine 10:345 (1992)	
	295	H-13	
,U	296	Hourvitz et al. (1996) "Reactogenicity and immunogenicity of a new recombinant hepatitis B Vaccine	
		4	
Exami	ner	Date	
Signature Considered			

Agelicatio.

Agelicatio.

Filing Date

Filing Name cation Number 09/724,869 INFORMATION DISCLOSURE November 28, 2000 STATEMENT BY APPLICANT First Named Inventor Juha Punnonen

(use as many sheets as necessary)

Group Art Unit	1627	JUN 1 0 2002
Examiner Name	Unassigned	
Attorney Docket Number	02-030310US	TECH CENTER 1600/2900
Date Submitted	May 21, 2002	IEUN OCHTEN 1000 230

Complete if Known

11.1	297	containing Pre S Antigens." <i>J Virol. Hepatitis</i> 3:37-42 <b>Howard</b> (1998) "Chemistry of the future: Exploitation of the power of biology." Book of Abstracts, 216th
pan	231	ACS National Meeting, Boston, August 23-27, BTEC-045 Apst #: 528494
~.	298	Hristov and Karadjov (1975) Vet Med Nauki 13:5
<b>\</b>	299	Huang, Sharon K.S. et al., "Antibody Responses to Melanoma/Melanocyte Autoantigens in Melanoma Patients," J. Invest. Dermatol. 111:662-7 (1998)
7	300	Hui, George S.N. et al., "Dominance of Conserved B-Cell Epitopes of the Plasmodium falciparum Merozoite Surface Protein, MSP1, in Blood-Stage Infections of Naïve Aotus Monkeys," Infect. Immun. 64:1502-1509 (1996)
	301	Hulskotte at al. (1998) "Towards an HIV-1 vaccine: lessons from studies in macaque models." Vaccine 16:904-915
	302	<b>Hurtado et al.</b> (1996) "Identification of Domains in Canine Parvovirus VP2 Essential for the Accembly of Virus-Like Particles." <i>J. Virol</i> 70:5422-5429
V	303	lacono-Connors et al., Virus Res. 43:125-136 (1996)
MAN A	304	Irvine, K.R. et al., "Cytokine Enhancement of DNA Immunization Leads to Effective Treatment of Established Pulmonary Metastases," Journal of Immunology, 156:238-245 (1996)
- poli	305	Jia et al. (1995) "A Novel virant of avain infectious bronchitis virus resulting from recombination among three different strains." <i>Arch Virol</i> 140:259-271
ſ	306	Jiang et al. (1999) "Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles." <i>Vaccine</i> 17:1005-1013
	307	Jiang et al., "Subtraction hybridization identified a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression," Oncogene 11:2477 (1995)
	308	Jiang et al., "The melanoma differentiation associated gene mda-7 suppresses cancer cell growth," Proc. Nat'l. Acad. Sci. USA 93:9160 (1996)
	309	Jin et al. (1998) "Recombinant Human Respiratory Synctial Virus (RSV) from cDNA and Construction of Subgroup A and B Chimeric RSV." Virology 251:206-214
A	310	Johnston, et al. (1997) "Genetic to genomic vaccination" Vol. 15, no. 8 pp 808-809
1	311	Kang et al. (1999) "Development of HIV/AIDS Vaccine Using Chimeric gag-env Virus-like Particles."  Biol. Chem 380:353-364
	312	Karandikar et al.,"CTLA-4: A Negative Regulator of Autoimmune Disease," J. Exp. Med. 184:783 (1996)
•	313	<b>Keck. Et al.</b> (1988) "In Vivo RNA-RNA Recombination of Coronavirus in Mouse Brain." <i>J. Virol.</i> 62:1810-1813
•	314 Keenan et al.,"Lack of Protection following immunisation with H. pylori outer membrane vesicles highlights antigenic differences between H. felis and H. pylori," FEMS Microbiol Lett. 161:21-7 (1993)  Khavari, (1997) Therapeutic gene delivery to the skin Molecular Medicine Today, Dec. 1997: 53  Khavari and Krueger (1997) Cutaneous Gene Therapy." Adv Clin Res Dermatologic Clinics 15(1) 35	
•		
•		
V	317	Khusmith et al. (1991) "Protection against malaria by vaccination with sporozoite surface protein 2 plus
		4
Examiner		Date
Signat	ture	Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

0 5 2002

TO ADEN Complete if Known Substitute for form 1449A-B/PTO Application Number 09/724,869 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT First Named Inventor **Juha Punnonen Group Art Unit** 1627 <del>JUN ( 0 200</del>2 **Examiner Name** Unassigned (use as many sheets as necessary) 02-030310US Attorney Docket Number IECH CENTER 1600/2900 **Date Submitted** May 21, 2002

	CS protein." Science 252:715
31	Kim et al., "In Vivo Engineering of a Cellular Immune Response by Coadministration of IL-12 Expression Vector with a DNA Immunogen," J. Immunol. 158:816 (1997)
31! ما تُعَامِر	8 pp 879-883.
102 71, 321	Kinney et al. (1997) "Construction of Infectious cDNA Clones for Dengue 2 Virus: Strain 16681 and Its Attenuated Vaccine Derivative, Strain PDK-53." Virology 230:300-308
10 W 32	Kinney et al., "Recombinant Vaccinia Virus/Benezuelan Equine Encephalitis (VEE) Virus Protects Mice from Peripheral VEE Virus Challenge," J. Virol. 62:4697 (1998)
Au 32:	Kleanthous et al., "Vaccine development against infection with Helicobacter pylori," Br. Med. Bull. 54:229-41 (1998)
Not 32:	, ,
€ 23°	Klinman, D.M. et al., "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," Journal of
pu 23	0 14 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The R3	Kobyashi, Yuzuru et al., "Antigenic Analysis of Japanese Encephalitis Virus by Using Monoclonal
+dv23	Kochel, Tadeusz et al., "Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice," Vaccine 15:547-552 (1997)
10 T 238	
17hi	Konishi et al.,"A Highly Attentuated Host Range-Restricted Vaccinia Virus Strain, NYVAC, Encoding the prM, E and NS1 Genes of Japanese Encephalitis Virus Prevents JEV Viremia in Swine," Virology 190:454 (1992)
HOT 240	Koopman et al., "Generation, intracellular transport and loading of peptides associated with MHC class 1 molecules," Curr. Opin. Immunol. 9:80-88 (1997)
im 24	Kramer and Fritz, "Oligonucleotide-Directed Construction of Mutations via Gapped Duplex DNA,"  Methods in Enzymol. 154:350-367 (1987)
fu 242	Kramer et al. "Improved Enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction of mutations," Nucl. Acids Res. 16:7207 (1988)
/ 243	Managed at 1994 and December 1994 at 1
244	Kramer et al., "The gapped duplex DNA approach to oligonucleotide-directed mutation construction," Nucl. Acids Res. 12:9441-9456 (1984)
24	16.1 A - 1 160-0
246	Krieger, M. et al., "Molecular Flypaper, Atherosclerosis, and Host Defense: Structure and Function of the Macrophage Scavenger Receptor," Cold Spring Harbor Symposia on Quantitative Biology 57:605-609 (1992)
247	Marian at al. 100 announcing of human interded this 4 into a high affinite automobile has a final angle and

		-
Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PT
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Group A

Group A

(use as many sheets as necessary)

S C	omplete if Known		
Application Number	09/724,869		
Filing Date	November 28, 2000	RECEIV	FD
First Named Inventor	Juha Punnonen		
Group Art Unit	1627	JUN 1 0 20	h2
Examiner Name	Unassigned		,
Attorney Docket Number	02-030310US 7	ECH CENTER 160	nionn
Date Submitted	May 21, 2002	LUIT OLIVI EN 100	0/2500

1248		Kuchroo et al., "B7-1 and B7-2 Costimulatory Molecules Activate Differentially the Th1/Th2	
NOT	2 70	Developmental Pathways: Application to Autoimmune Disease Therapy," Cell 80:707 (1995)	
on	249	Kunkel et al.,"Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection," Methods in	
	270	Enzymol. 154:367-382 (1985)	
	250	Kunkel, "The efficiency of oligonucleotide directed mutagenesis" Nucleic acids & Molecular Biology 2:	
10	200	124-135 (1988)	ļ
THE	251	Kunkel, "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection," Proc. Nat'l. Acad.	
	231	Sci. USA 82:488-492 (1985)	
$D_{i-1}$	252	Lagranderie et al. (1993) "BCG-induced protection in guinea pigs vaccinated and challenged via the	
- Reli	202	respiratory route." Tubercle and Lung Disease 74:38-46	
	253	Lai et al. (1991) *Infectious RNA transcribed from stabily cloned full-length cDNA of dengue type 4	
1 1	200	Virus." Proc. Nat'l Acad. Sci. USA 88:5139-5143	
	254	Lanar et al. (1996) "Attanuated Vaccinia Virus-Circumsporoziote Protein Recombinants Confer	$\dashv$
~	204	Protection against Rodent Malaria." Infect Immun 64:1666-1671	İ
	OFF	Lanciotti et al. (1994) "Molecular evolution and epidemology of dengue-3 viruses." J Gen Virol. 75:65-	
•	255	75	
	256	Laud et al., Human Immunol. 50:91-102 (1996)	
	200		
,	257	Larsen et al., Long Term acceptance of Skin and Cardiac Allografts After Blocking CD40 and CD28	
		Pathways,"Nature 381: 434 (1996).	
	258	Leary et al.,"Active Immunization with Recombinent V Antigen from Yersinia Pestis Protects Mice	
		against Plague," Infect. Immun. 3:2854 (1995)	
	259	Lee et al., (1997) "Generation of an Infectious cDNA of a highly cardiovirulent coxsakievirus B3(CVB3m)	
		and comparasion to other infectious CVB cDNAs." Virus Res 50:255-235	
	260	Lee et al., "Optimal Induction of Hepatitis C Virus Envelope-Specific Immunity by Bicistronic Plasmid	1
-00		DNA Inoculation with the Granulocyte-Macrophage Colony-Stimulating Facter Gene," J. Virol 72:8430-6	
		(1998)	
	261	Lehrer et al. (1998) "Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis." FEMS	
	-	Immunol. Med. Mircobiol. 21:71-77	
	262	Leung et al. (1989) Technique 1(1):11-15	
H		Lichard (4007) III.	
1	263	Li et al. (1997) "Expression of the Human Papillomavirus Type 11 L1 Capsid Protein in Escherichia coli.	
$\vdash$		" J. Virol 71(4):2988-2995	
	264	Li et al.,"Cloning and functional characterization of a subunit of the transporter associated with antigen	1
<u> </u>		processing," Proc. Natl. Acad. Sci USA 94: 8708-8713 (1997).	
Not	265	Liao et al. (1990) Gene 107-111	ħ
200		Liao et al., STRL22 is a Receptor for the CC Chemokine MIP-3α," Biochem. and Biophys. Comms. 236:	{}
"	266	212-217 (1997).r	K
, 3		Liblau et al. "Th1 and Th2 CD4+ cells in the pathogenesis of organ-specific autoimmune diseases,"	
file	267	Immunol. Today 16:34-38 (1995)	1
<del>                                    </del>		Liem et al. (1994) Nucleic Acids Res 22(9):1613-1619	
How	268	Light et al. (1994) Nucleic Acids (188, 22(8), 1019-1018	
4			

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUN 0 5 2002 Application Name

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	G C	omplete if Known
	Application Number	09/724,869
£	⊋Biffing Date	November 28, 2000
	First Named Inventor	Juha Punnonen
	Group Art Unit	1627 JUN 1 0 2002
	Examiner Name	Unassigned
	Attorney Docket Number	02-030310US TECH CENTER 1600/2900
	Date Submitted	May 21, 2002

WIT	000	Lieschke et al.,"Bioactive murine and human interleukin-12 fusion proteins which retain antitumor
a me	269	activity in vivo," Nature Biotech. 15:35 (1997)
, , , ,	270	Limbach and Paoletti (1996) "Non-replicating expression vectors: applications in vaccine development
100	2/0	and gene therapy." Epidemol. Infect. 116:241-256
ì	271	Lowe et al. (1997) "Human Papillamavirus Typw 2 (HPV-11) Nutralizing Antibobies in the Serum and
الم	2/1	Genitial Mucosal Secretions of African Green Monkeys Immunized with HPV-11 Virus-like particles
1 1		Expressed in Yeast." J. Invect Dis 176:1141-1145
	272	Lowman, Henry B. and Jame A. Wells, "Affinity Maturation of Human Growth Hormone by Monovalent
1 1	212	Phage Display," J. Mol. biol. 234:564-578 (1993)
	273	Lowman, Henry B. and James A. Wells, "Monovalent Phage Display: A Method for Selecting Variant
11-	275	Proteins from Random Libraries," Methods: A Companion to Methods Enz. 3(3):205-216 (1991)
MOY,	274	Lu, Zhijian et al., "Expression of Thioredoxin Random Peptide Libraries on the Escherichia coli Cell
N 3~14		Surface as Functional Fusions to Flagellin: A System Designed for Exploring Protein-Protein
		Interactions," Bio/Technology 13:366-372 (1995)
V	275	Luytjes et al. (1989) "Amplification, Expressionand Packaging of a Foreign Gene by Influenza Virus."
700	/	Cell 59:1107-1113
l i	276	MacKay et al. (1981) "Production of immunology active surface of hepatitis B virus by Escherichia coli."
3		Proc. Natl. Acad. Sci USA 78:4510-4514
h	277	Mandl et al. (1997) "Infectious cDNA clones of tick-borne encephalitis virus European subtype protopic
<u> </u>		strain Neudoerfl and high virulence strain Hypr." J. Gen. Virol 78:1049-1057
	278	Marchetti, Marta et al., "Protection against Helicobacter pylori infection in mice by intragastric
J		vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin
		(LT) as adjuvant," Vaccine 16:33-7 (1998)
NOF 279		Marusina et al.,"Allelic Variation in the Mouse Tap-1 and Tap-2 Transporter Genes," J. Immunol.
		158:5251-5256 (1997)
1 280		Mattheakis, Larry C. et al., "An in vitro polysome display system for identifying ligands from very large
		peptide libraries," Proc. Nat'l. Acad. Sci. USA 91(19):9022-6 (1994)  McAtee, C. Patrick et al., "Identification of Potential Diagnostic and Vaccine Candidates of Helicobacter
12	281	pylori by "Proteome" Technologies," Helicobacter 3:163-9 (1998)
<b>- ' '</b>	<del>                                     </del>	McAtee, C. Patrick et al., "Identification of Potential Diagnostic and Vaccine Candidates of Helicobacter
( )	289	pylori by Two-Dimensional Gel Electrophoresis, Sequence Analysis, and Serum Profiling," Clin. Diagn.
1+0	<b>Y</b>	Lab. Immunol. 5:537-42 (1998)
1		McCutcheon et al. "A senstive ELISPOT assay to detect low-frequency human T lymphocytes,", J.
MOP	290	Immunol. Methods 210:149-66 (1997)
	001	McGregor, Duncan, "Selection of Proteins and Peptides from Libraries Displayed on Filamentous
1 th	291	Bacteriophage," Mol Biotechnol. 6(2):155-62 (1996)
		Melen et al., "Enzymatic Characterization of Interferon-Induced Antiviral GTPases Murine Mx1 and
'	292	Human MxA Proteins," J. Biol, Chem. 269: 2009-2015 (1994).
<del>    -   -                              </del>	000	Mendoza, R.B. et al. (1997) "Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154)
'	293	on gene immunization" J. Immunol Dec. 15;159(12):5777-81 ABSTRACT ONLY
1	204	Metz et al. (1996) "Bicistronic and Two-Gene Retroviral Vectors for Using MDR1 as a Selectable Market
🗤	294	and a Therapeutic Gene." Virology 217:230-241
L		

	I	
Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUN 0 5 2002 Substitute for form 1449A-B/PTO
INFORMATION DISCLOSURE Complete if Known Application Number 09/724,869 November 28, 2000 Filing Date STATEMENT BY APPLICANT First Named Inventor Juha Punnonen **Group Art Unit** 1627 **Examiner Name** Unassigned (use as many sheets as necessary) **Attorney Docket Number** 02-030310US **Date Submitted** May 21, 2002

tow	295	Meulenberg et al. (1998) "An Infectious cDNA Clone Porcine Reproductive and Respiratory Syndrom Virus." Coronaviruses and Arteriviruses 440:199-206	ie			
Í	296	Meulenberg et al. (1998) "Infectious Transcrips from Cloned Genome-Length cDNA of Porcine Reproductive and Respiratory Syndrome Virus." J. Virol. 72:380-387				
	297	Managed at (4000) ID air at the state of the				
	298	Minshull, J. and Willem P.C. Stemmer, "Protein evolution by molecular breeding," Current Opinion in Chemical Biology 3:284-290 (1999)				
-,	299	Mittelholzer et al. (1997) "Generation of cytopathogenic RNA of classical swine fevor in persistently infected porcine cell lines." Virus Res 51:125-137				
	300	<b>Monaco</b> , "Pathways for the processing and presentation of antigens to T cells," J. Leukocyte Biol. 57:543-57 (1995)				
	301	Morita et al. (1987) "Recombinant vaccinia virus LC16m0 or LC1m8 that expresses hepatitus B surfa antigen while preserving the attention of the parental virus." Vaccine 5:65-70	ice			
	302	Mosmann and Coffman, Adv. Immunol. 46:111 (1989)				
	303	Moss (1994) "Replicating and Host-Restricted Non-Replicating Vaccina Virus Vectors for Vaccine Development." Dev. Biol. Stand 82:55-63				
	304	Mundt and Vakharia (1996) "Synthetic transcripts of double-stranded Birnavirus genome are infectious." Proc Nat'l Acad. Sci USA 93:11131-11136				
KUK	305	N. Miller et al., (1995) "Targeted vectors for gene therapy," FASEB J., 9, pp. 190-199.				
0	306	Nakamaye and Eckstein, "Inhibition of restriction endonuclease Nci I cleavage by phosphorothioate groups and its application to oligonucleotide-directed mutagenesis," Nucl. Acids Res. 14:9679-9698 (1986)				
July 3	307	Nambiar et al.,"Total Synthesis and Cloning of a Gene Coding for the Ribonuclease S Protein," Scien 223:1299-1301 (1984)	се			
you.	308	Nazerian et al. (1996) "Protection and synerhism by Recombinant Fowl Pox Vaccines Expressing Genes from Marek's Disease Virus." Avian Dis. 40:368-376				
<u>+</u> :	309	Nemoto, Naoto et al., "In vitro virus: Bonding of mRNA bearing puromycin at the 3'-terminal end to the C-terminal end of its encoded protein on the ribosome in vitro," FEBS Lett. 414(2):405-8 (1997)	Nemoto, Naoto et al., "In vitro virus: Bonding of mRNA bearing puromycin at the 3'-terminal end to the C-terminal end of its encoded protein on the ribosome in vitro." FEBS Lett. 414(2):405-8 (1997)			
1	310	Ness, J. et al., (1999) "DNA shuffling of subgenominc sequences of subtilisin." Nature Biotechnology 17:893-896.				
	311	Neurath, A.R. et al., "Monoclonal Antibodies to Hepatitis BSurface Antigen (HBsAg) with Anti-a Specificity Recognize A Synthetic Peptide Analogue (S135-155) with Unmodified Lysine (141)," J. Viro Methods 9:341-346 (1984)	ol.			
	312	Ni and Barrett, "Nucleotide and deduced amino acid sequence of the structural protein genes of Japanese encephalitis viruses from different geographical locations," J. Gen. Virol. 76:401 (1995)				
	313	Notka et al. (1999) "Constructon and Characterization of Recombinant VLPs and Semliki-Forest Viru Live Vectors for Comparative Evaluation in the SHIV Monkey Model." <i>Biol Chem</i> 380:341-352	s			
	314	ON-1 K T -4-1 #Db di-d 4 -1 # -1 # -1 # -1 # -1 # -1 # -1 #				
	315	Oda Kobe J. Med. Sci. 22:123 (1976)				
•		1 4				
Exami	iner	Date				
Signat	ture	Considered				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUN 0 5 2002 B

Complete if Known Substitute for form 1449A-B/PTO 09/724,869 Application Number INFORMATION DISCLOSURE November 28, 200 Filing Date Juha Punnonen STATEMENT BY APPLICANT First Named Inventor **Group Art Unit** 1627 <del>JUN 1 0 2002</del> Unassigned **Examiner Name** (use as many sheets as necessary) 02-030310US **Attorney Docket Number** May 21, 2002 **Date Submitted** 

The.	316	Oggioni, M.R. and Pozzi, G., "A host-vector system for higordonii," Gene 169:85-90 (1996).	eterologous gene ex	pression in Streptococcus	1
3	317	Orme (1997) "Progress in the development of new vaccir Dis 1:95-100	es against tuberculo	sis." Int. J. Tuberc. Jung.	٦
d	318	Ortmann et al.,"A Critical Role for Tapasin in the Assembly and Function of Multimeric MHC Class 1- TAP Complexes," Science 277: 1306-1309 (1997).			٦
	319	Paoletti et al. (1995) "Highly Attenuated Poxvirus: HYVAC, ALVAC and TROVAC," Dev Biol Stand 84:159-163			
	320	Park and RajBhandary (1998) "Tatracycline-Regulated Suppression of Amber Codons in Mammalian Cells." <i>Mol Cell Biol</i> 18:4418-4425			
	321	Parren, Paul W.H.I. et al., "Relevance of the antibody restype 1 envelope to vaccine design," Immunol. Lett. 57:105		n immunodeficiency virus	
J.	322	Parronchi et al., "IL-4 and IFN (☐ and ☐) Exert Opposite Cytolytic Potential by Th1 or Th2 Human T Cell Clones," J	Regulatory Effects of	n the Development of (1992)	
NOT	,323	Pascopella et al. (1994) "Identification of a genome fragn Agents & Disease 2:282-284	nent of Mycobacteriu	m tuberculosis." Infectious	
+20	324	Pascopella et al. (1994) "Use of In Vivo complementation genomic fragment associated with virulence." Infection &			
120	325	Pasquini S. et al. (1997) " Cytokines and costimulatory m Biol Aug: 75(4):397-401 ABSTRACT ONLY			╗
1027	326	Patten, P.A. et al., "Applications of DNA Shuffling to Phar Biotechnology, 8:724-733 (1997)	maceuticals and Vac	cines," Current Opinion in	
Jares.	327	Paul and Seder, "Lymphocyte Responses and Cytokines			$\Box$
- John	328	Paulusma et al. (1996) "Congenital jaundice in rats with a protein gene." Science 271:1126-1128			
ij	329	Pelletier, Joelle N., (2001) "A Rachitt for our toolbox" Nat			╛
-	330	Peng et al. (1998) "Papillomavirus Virus-like Particles Can Deliver Defined CTL Epitopes to the MHC Class 1 Pathway." Virology 240:147-157			
	331	Penzes et al. (1996) "Replication and Packaging of Coror Lacking a Long Open Reading Frame." J. Virol 70:86660-	8668		
1	332	Phizicky, Eric M. et al., "Protein-Protein Interactions: Med Rev. 59(1):94-123 (1995)			
NX	.333 	Pisetsky, D.S., "Immune Activation by Bacterial DNA: A (1996).			
70°	334	Pletnev, A.G. et al., Chimeric Tick-Borne Encephalitis an on Neurovirulence in Mice," J. Virol. 67(8):4956-4963 (1996)	93)		
Tan	)335	Polo et al. (1999) "Stable alphavirus packaging cell lines for Sidbis virus-and Semlike Forest virus-derived vectors." Proc Nat'l Acad. Sci USA> 96:4598-4603		Semlike Forest virus-	
No Ch	336	Porcelli (1995) Adv. Immunol 59:1			
mp	337	Powis et al.,"Polymorphism in a second ABC transporter gene located within the class II region of the human major hisotcompatibility complex,"Proc. Nat'l. Acad. Sci. USA 89:1463-1467 (1996)			
Ü			Ç	<del>" "</del>	٦
Exami	iner		Date		
Signature			Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

•
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

C	omplete if Known		Ì
Application Number	09/724,869		1
Filing Date	November 28, 20	00	1
First Named Inventor	Juha Punnonen		L
Group Art Unit	1627	RECEIVE	L
Examiner Name	Unassigned		
Attorney Docket Number	02-030310US	JUN 1 0 2002	
Date Submitted	May 21, 2002		1

		L Promock et al. (1996) Nature Mad 2:1174	$\Omega\Omega T$
	338	Premack et al. (1996) Nature Med. 2:1174	a <del>ol</del>
TRU	339	<b>Pryor et al.</b> (1998) "Growth restriction of dengue virus type 2 by site-specific mutagenesis of virus-encoded glycoproteins." <i>J. Gen Virol.</i> 79:2631-2639	
is it	340	Punnonen et al (1998) "Evolution of genetic vaccines by DNA shuffling." Keystone Symposia on Molecular and Cellular Biology, Molecular Aspects of Viral Immunity, Abstract #227, Tamarron, CO, February 16-20, 1998	
tow	341	Punnonen et al. (1997) "Evolution of DNA Vaccine vectors by gene shuffling." The First Gordon Conference on Genetic Vaccines/DNA Vaccines, Plymouth State College, Plymouth, NH, July 20-25, 1997	
John	342	Punnonen et al. J. Exp Med. 185:993-1004	
for fe	343	Punnonen et al., "Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells," Proc. Nat'l. Acad. Sci. USA 90:3730 (1993)	
他	344	Puri et al. (1998) "Complete Nucleotide Sequences Analysis of a Western Pacific Dengue-1 Virus Strain." Virus Genes 17:85-88	
Î,	345	Racke, Michael K. et al., "Cytokine-induced Immune Deviation as a Therapy for Inflammatory Autoimmune Disease," J. Exp. Med. 180:1961-66 (1994)	
	346	Rahden-staron et al. (1991) Biochem & Biophy Res. & Commun. 177(2):597-602	
V	347	Raj and Jones (1997) "Growth of infectious bronchitis virus vaccines in oviducts derived from oestrogen-treated chicks and embryos." <i>Vaccine</i> 15:163-168	
orter	348,	Reiser et al., "Cloning and expression of a cDNA for the T-cell-activating protein TAP," Proc. Nat'l. Acad. Sci. USA 85:2255-2259 (1988)	
TW	349	Roden et al. (1996) "In Vitro Generation and TypeSpecific Neutralization of a Human Papillomavirus Type 16 Viron Pseudotype." <i>J. Virol.</i> 70:5875-5883	
į	350	Roggenkamp et al., "Passive Immunity to Infection with Yersinia spp. Mediated by Anti-Recombinant V Antigen is Dependent on Polymorphism of V Antigen," Infect. Immun. 65:446 (1997)	
1	351	Roncarolo et al. "Human T- and B-cell functions in SCID-hu mice," Semin. Immunol. 8: 207 (1996)	
	352	Sagazio et al. (1998) "Antigenic characterization of canine parvovirus strains isolated in Italy." <i>J. Virol. Methods</i> 73:197-200	
J	353	Saggio et al. (1995) "CNFT Variants with increased biological potency and receptor selectivity define a functional site of receptor interaction." <i>EMBO Journal</i> 14(13):3045-3054	
红什	૮ <b>૩</b> 54	Sakmar and Khorana, "Total synthesis and expression of a gene for the a-subunit of bovine rod outer segment guanine nucleotide-binding protein (transducin), Nucl. Acids Res. 14:6361-6372 (1988)	
	)355	Sanz et al. (1994) "Genetic heterogeneity of the attachment glycoprotein G among A respiratory syncytial virusus." Virus Res 33:203-217	
Till	356	Saurmann et al. (1990) "Molecular Cloning and Characterization of a German HIV-1 Isolate." AIDS Res. Hum Retroviruses 6:813-823	
	, 357	Sayers et al. "Strand specific cleavage of phosphorothioate-containing DNA by reaction with restriction endonucleases in the presence of ethidium bromide,", Nucl. Acids Res. 16:803-814 (1988)	

	[	
Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	/01	PE	4
R	JUN 0	5 2002	600
H			и

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	<u> </u>	
1	J U	omplete if Known
I	Application Number	09/724,869
	Filing Date	November 28, 2000 R - ( - V -
	First Named Inventor	Juha Punnonen
	Group Art Unit	1627 JUN 1 0 2002
	Examiner Name	Unassigned
İ	Attorney Docket Number	02-030310US TECH CENTER 1600/2900
	Date Submitted	May 21, 2002

N. O.T.	357	Sayers et al., "5'-3' Exonucleases in phosphorothioate-based oligonucleotide-directed mutagenesis," Nucl. Acids Res. 16:791-802 (1988)					
TOU	358	Schatz, Peter J. et al., "[10] Screening of Peptide Libraries Linked to lac Repressor," Methods Enzymol. 267:171-91 (1996)					
1	359	Schmaljohn, A.L. et al., "Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis," Nature 297:70 (1982)					
J.	360	Schwarz et al. (1957) "Modification of Infevtious Bovine Rhinotrachetis (IBR) Virus in Tissue Culture and Development of a Vaccine." <i>Proc Soc Exp. Biol Med.</i> 96:453-458					
"Ozu	361	Schwarz et al. (1958) "Propagation and Modification of Infactious Bovine Rhinotrachetis (BR) Virus in Porcine Kidney Tissue Culture." <i>Proc Soc. Exp. Biol. Med</i> 97:680-683					
+4	362	Scott, Jamie K. and George P. Smith, "Searching for P Science 249:386-388 (1990)		an Epitope Library,"			
7	363	Seliger et al., "TAP off - tumors on," Immunol. Today 18:	292-299 (1997).				
7	364	Sharma and Graham (1982) "Influence of Material Antibo Cell-Associated ans Cell-Free Marek's Disease Vaccine."					
	365	Sheu et al. (1995) "Deletion or alteration of hydrophobic a					
		domains of Hepatitis B Surface antigen enhances its prod					
J	366	Shouval et al. (1994) "Improved immunogenicity in Mice hepatitis B Vaccine containing pre-S1 and pre-S2 antigen vaccines." <i>Vaccine</i> 12(15):1453-1459	s as compared with	conventional yeast-derived			
NOT	367	Sizemore et al., "Attenuated Shigella as a DNA Delivery Science 270:299-302 (1995)		diated Immunization,"			
Fire	368	Smith, "In Vitro Mutagenesis," Ann. Rev. Genet. 19:423-4	162 (1985)				
TOU	369	Sokolic et al. (1996) "A Bicistronic Retrovirus Vector Cor Entry Site Allows for Correct of X-Linked CGD Selection f					
	370	Soong et al. (1998) "DNA shuffling as a tool to evolve de papers presented at the 1998 meeting on Gene Therapy, Spring Harbor, New York, September 23-27, 1998	p. 228 Cold Spring I	Harbor Laboratory, Cold			
1	371	Soong et al. (1998) "Directed evolution of novel retroviral Programs & Abstracts, 1st Annual Meeting of the America Washington, May 28-31, 1998	tropisms by DNA stan Society of Gene T	nuffling." Abstract #97, herapy, Seattle,			
Dog	372 بار	Soong et al. (1998) "Directed evolution of novel retroviral tropisms by DNA shuffling." Abstracts of papers presented at the 1998 meeting on Retroviruses, Cold Springs Harbor Laboratory, Cold Spring Harbor, New York, May 26-31, 1998					
their	373	Sosnovtsev et al. (1998) "Cleavage of the Feline Calicivirus Capsid Precurrsor Is Mediated by a Virus- Encoded Proteinase." <i>J. Virol</i> 72:3051-3059					
ß	374	Srinivasan et al. (1987) "Molecular characterization of human immunodeiciency virus from Zaire."  Gene 52:71-82					
	375	Stemmer (1991) "A 20-Minute ethidium bromide/high-salt extraction protocol for plasmid DNA."  BioTechniques 10(6): 726					
4	376	Stemmer (1994) Nature 370:389					
			Ţ				
Exami	iner		Date				
Signat	ture	Considered					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TECH CENTER 1600/2900

THATE! Substitute for form 1449A-B/PTO Complete if Known **Application Number** 09/724,869 November 28, 2000 INFORMATION DISCLOSURE **Etting Date** STATEMENT BY APPLICANT First Named Inventor Juha Punnonen **Group Art Unit** 1627 <del>JUN 1 0 2002</del> Unassigned **Examiner Name** (use as many sheets as necessary) **Attorney Docket Number** 02-030310US

May 21, 2002

اروعي	077	Stemmer (1996) "DNA sequence evolution by sexual PCR." Experientia (Basel) 52(ABSTR): A25
The	377	
J:	378	Stemmer (1998) "Directed evolution of proteins, pathways, episomes and viruses by DNA shuffling," FASEB Journal 12(8): A1303
1	379	Stemmer and Soong, (1999) "Molecular breeding of viruses for targeting and other clinical properties," Tumor Targeting 4:1-4
7	380	Stemmer et al. (1991) "Expression of antibody Fv Fragments specific for a heavy metal chelate (indium-EDTA) in E. coli." Journal of Cellular Biotechnology Supplement 0 (15 PART G):217
2	381	Stemmer et al. (1992) "Enzymatic inverse PCR: a restriction site independent, single-fragment method for high-efficiency, site-directed mutagenesis." BioTechniques 13(2): 214, 216, 218-220
7	382	Stemmer et al. (1993) "Increased antibody expression from Escherichia coli through wobble-base library mutagenesis by enzymatic inverse PCR>" Gene 123(1): 1-7
2	383	Stemmer et al. (1993) "Selection of an active single chain Fv antibody from a protein linker library prepared by enzymatic inverse PCR>" Biotechniques 14(2): 256-265
1	384	Stemmer et al. (1997) "Molecular evolution of genetic vaccines by DNA shuffling." FASEB Journal 11(9): A1124 17TH International Congress of BiochemSan Francisco, CA USA (2/24-29,)
lot	385	Stemmer et al.,(1995) "Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides," Gene 164:49-53
01	386	Stemmer, "DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution," Proc. Natl. Acad. Sci. USA 91:10747-10751 (1994)
Eile	387	Stemmer, W.P.C., "Rapid evolution of a protein in vitro by DNA shuffling," Nature 370:389-391 (1994)
Ί	388	Stemmer, W.P.C., "Searching Sequence Space," Biotechnology 13:549-553 (1995)
	389	Stemmer, W.P.C., "Sexual PCR and Assembly PCR," The Encyclopedia of Molecular Biology, VCH Publishers, New York pp. 447-457 (1996)
	390	Stemmer, W.P.C., "The Evolution of Molecular Computation," Science 270:1510 (1995)
	391	Stern et al., "Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells," Proc. Nat'l. Acad. Sci. USA 87:6808 (1990)
1	392	Stohwasser et al., "Molecular cloning of the mouse proteasome subunits MC14 and MECL-1: reciprocally regulated tissue expression of interferon -γ-modulated proteasome subunits," Eur. J. Immunol. 27:1182-1187 (1997)
rou	393ر	Subbarao et al. (1993) Rescue of an Influenza A Virus Wild-type PB2 Gene and a Mutant Derivative Bearing a Site-Specific Temperature-sensitive and Attenuating Mutation." J. Virol. 67:7223-7228
The	394	Sugimoto et al. (1994) "Characteristics of an attenuated vaccinia virus strain, LC16m0 and It's recombinant virus vaccines." Vaccine 12:675-681
DW	395	Sugimoto et al. (1995) Retroviral Coexpression of a Multidrug Resistance Gene (MDR1) and Human a-Galactosidase A for Gene Therapy of Febry Disease." Human Gene Ther 6:905-915
)ot	396	<b>Tahara et al.</b> , "IL-12 Gene Therapy Using Direct Injection of Tumors with Genetically Engineered Autologous Fibroblasts," Human Gene Therapy 6:1607 (1995)
~	397	Tan et al., "Characterizationof Recombinant Extracellular Domain of Human Interleukin-10 Receptor," J. Biol. Chem. 270:12906 (1995)

**Date Submitted** 

	[	q
Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

THAT MADE INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

C	omplete if Known		_
Apptication Number	09/724,869	DECEIVE	()
⊾ <b>F</b> ®ng Date	November 28, 20	00 RECEIVE	
First Named Inventor	Juha Punnonen	0 2002	
Group Art Unit	1627	JOH 1 0 500c	
Examiner Name	Unassigned	750 1000	Moci
Attorney Docket Number	02-030310US	TECH CENTER 1600	12301
Date Submitted	May 21, 2002	TLOTT	

The	398	Tang et al. (1992) "Genetic immunization is a simple method for eliciting an immune response." Nature 356:152			
1	399	Tang et al., "Vaccination onto bare skin," Nature 388: 729-730 (1997).			
,	400	Tano et al. (1990) Proc. Nat'l Acad Sci USA 87:686-690			
	401	Tartagila et al. (1992) "NYVAC: A Highly Attenuated Strain of Vaccinia Virus." Virology 188:217-232			
1	402	Tascon, Richard E. et al., "Vaccination against tuberculosis by DNA injection," Nat. Med. 2:888-92 (1996)			
J	403	<b>Taylor et al.</b> , "The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA," Nucl. Acids Res. 13:8765-8787 (1985)			
Bet	404	<b>Taylor et al.</b> , "The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare nicked DNA," Nucl. Acids Res. 13:8749-8764 (1985)			
The	405	<b>Thierfelder et al.</b> "Requirement for Stat4 in interleukin-1-2-mediated responses of natural killer and T cells", Nature 382:171 (1996)			
the	406	<b>Todd</b> (1974) "Development of Intranasal Vaccination for the Immunization of Cattle Against infectious Bovine Rhinotrachetis." <i>Can. Vet J.</i> 15:257-259			
1	407	Trudel et al., "pGATA: A Positive Selection Vector Based on the Toxicity of the Transcription Factor GATA-1 to Bacteria," Biotechniques 20:684-693 (1996).			
	Tytgat, G.N.,"Review article: practical management issues for the Helicobacter pylori-infected parisk of gastric cancer,"Aliment. Pharmacol. Ther. 12(1):123-8 (1998)				
	409	Ugen et al. (1994) "DNA inoculation as a novel vaccination method against retroviruses with rheumatic disease associations." <i>Immunol. Res.</i> 13:154-162.			
	410 Ulmer et al. (1993) "Heterologous protection against influenza by injection of DNA encoding a viral protein." Science 259:1745				
	411	Ulmer et al. (1996) "ELI's coming: expression library immunization and vaccine antigen discovery."  Trends im Microbiology 4(5):170-171			
	412	Valle amd Falgout (1998) "Mutagenesis of the NS3 Protease of Dengue Virus Type 2." J. Virol 72:624-632			
	413	van Dinten et al. (1997) "An Infectious arterivirus cDNA clone." Proc. Nat'l Acad. Sci USA94:991-996			
	414	VanCott et al., "Antibodies with Specificity to Native gp120 and Neutralization Activity against Primary Human Immunodeficiency Virus Type 1 Isolates Elicited by Immunization with Oligomeric gp160," J. Virol. 71:4319-4330 (1997)			
	415	Vassilev et al. (1997) "Authentic and Chimeric Full-length Genomic cDNA Clones of Bovine Viral Diarrhea Virus That Yeild Infectious Transcrips." <i>J. Virol</i> 71:471-487			
	416	Velzing et al. (1999) "Induction of protective immunity against Dengue virus type 2." Vaccine 17:1312-1320			
	417	Villinger et al., "Comparative Sequence Analysis of Cytokine Genes from Human and Nonhuman Primates," J. Immunol. 155:3946-3954 (1995)			
1	418	Walther et al. (1996) "Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting." <i>J. Mol. Med.</i> 74:379-392			

Examiner	Date	3
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

M O S L AND TO

Substitute for form 1449A-B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Co	omplete if Known	
Application Number	09/724,869	
Filing Date	November 28, 2	000 RECEIVED
First Named Inventor	Juha Punnonen	
Group Art Unit	1627	HIN 1 0 2002
Examiner Name	Unassigned	0 011
Attorney Docket Number	02-030310US	TECH CENTER 1600/2900
Date Submitted	May 21, 2002	IEOU OF MELL 1000/5000

Tão	419	Acad. Sci 186-196				
í	420	Wang et al. (1993) "Gene inoculation generates immune responses against human deficiency virus type 1." Proc. Nat'l Acad. Sci. USA 90:4156-4160				
	421	Walunas et al., "CTLA-4 Can Function as a Negative Regulator of T Cell Activation," Immunity 1:405 (1994)				
NOT	422	Wells et al., "Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites," Gene 34:315-323 (1985)				
Fry FOU	423	Wells et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin," Phil.  Trans. R. Soc. Lond. A317:415-423 (1986)				
TOU	424	Wermeille, Joel et al., "The eradication treatments of Helicobacter pylori," Pharm. World Sci. 20:1-17 (1998)				
1	425	Whelan et al. (1995) "Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones." <i>Proc. Nat'l. Acad. Sci. USA</i> 92:8388-8392				
	426	Whitacre et al.,"Treatment of Autoimmune Disease by Oral Tolerance to Autoantigens," Clin. Immunol. Immunopathol. 80: S31-9 (1996).				
	427	Wiertz et al., "SEC61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction," Nature 384: 432 (1996).				
	428	Wiertz et al., "The Human Cytomegalovirus US11 Gene Product Dislocates MHC Class 1 Heavy Chains from the Endoplasmic Reticulum to the Cytosol," Cell 84: 769-779 (1996).				
	429	Williams et al. (1993) "Genetic Infection Induces Protective In Vivo Immune Response." DNA & Cell Biology 12(8):675-683				
	430	Williams et al. (1994) "Immunotherapeutic strategies targeting rheumatiod synovial T-cell receptors by DNA inoculation." Immunol. Res 13:145-153				
	431	Winther et al. (1998) "Viral-Induced Rhinitis." Am J. Rhinol 12:17-20				
•	432	Wisniak et al. (1974) "Hydrogen Solubililty in Joboba Oil." JAOCA 51:482-485				
	433	Wloch et al., "The Influence of DNA Sequence on the Immunostimulatory Properties of Plasmid DNA Vectors," Hum. Gene Ther. 9:1439-1447 (1998)				
	434	Woody, Mary Alice et al., "Staphylococcal enterotoxin B mutants (N23K and F44S): biological effects and vaccine potential in a mouse model," Vaccine 15(2):133-139 (1997)				
(.	435	Wright et al. (1998) "Humane endpoints are an objective measure of morbidity in Venezelan encephalomyelitis virus infection of mice,' Arch Virol 143:1155-1162				
	436	Xiang et al. (1994) "A Simple method to test the ability of individual viral proteins to induce immune responses." J. Virological Methods 47:103-116				
	437	Xiang, Z. et al., "Manipulation of the Immune Response to a Plasmid-Encoded Viral Antigen by Coinoculation with Plasmids Expressing Cytokines," Immunity 2:129-135 (1995)				
	438	Yanagi et al. (1997) "Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee." <i>Proc Nat'l Acad. Sci. USA</i> 94:8738-8743				
	439	Yanagi et al. (1999) "In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone." <i>Proc. Nat'l Acad. Sci USA</i> 96:2291-2295				
V.	440	Yao et al. (1998) "Generation of Mutant Infectious Bursal Disease Virus That Does Not Cause Bursal				
Exami	ner	Date				
Signat	ure	Considered				
		the state of the s				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

ha 3011 '	<u> </u>	
B	omplete if Known	
<b>W</b> .	Application Number	09/724,869
A THE	Application Number  Application Number  Application Number	November 28, 2000
	First Named Inventor	Juha Punnonen HEUEIVEU
	Group Art Unit	1627
	Examiner Name	Unassigned JUN : 0 2002
<i>(</i> )	Attorney Docket Number	02-030310US
	Date Submitted	May 21, 2002 TECH CENTER 1600/290

•		Leaions." J. Virol. 72:2647-2654			
tai	441	Yu et al. (1995) "Functional cDNA Clones of the Human Respiratory Syncytial (RS) Virus " J. Virol 69:2412-2419			
iki	,442	Zamvil, Scott S. and Lawrence Steinman, "The T Lymphocyte in Experimental Allergic Encephalomyelitis," Ann. Rev. Immunol. 8:579-621 (1990)			
201	443	<b>Zanelli et al.</b> (1993) "Epitope mapping of human thyroid peroxidase defined seven epitopes reconized by sera from patients with thyroid pathologies." <i>Cell. &amp; Mol Biol.</i> 39(5):491-501			
~ie	444	Zhang, J. et al., "Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening," Proc. Natl. Acad. Sci. USA 94:4504-4509 (1997)			
+RU	445	Zhong et al. (1998) "Idenification and Characterization of an RNA-Dependent RNA Polymerase Activity within the Nonstructural Protein 5B Region of Bovine Viral Diarrhea Virus," <i>J. Virol.</i> 72:9365-9369			
Foir Point	446	<b>Zhong, Weimin et al.,</b> "Therapeutic passive vaccination against chronic Lyme disease in mice," Proc. Nat'l. Acad. Sci. USA 94:12533-12538 (1997)			
pat	447	Zoller and Smith, "Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA," Nucl. Acids res. 10:6487-6500 (1982)			
,~-	448	<b>Zoller and Smith,</b> "Oligonucleotide-Directed Mutagenesis: A Simple Method using Two Oligonucleotide Primers and a Single-Stranded DNA Template," Methods in Enzymol. 154:329-350 (1987)			
file	449	Zoller and Smith, "Oligonucleotide-Directed Mutagenesit of DNA Fragments Cloned into M13 Vectors," Methods in Enzymol. 100:468-500 (1983)			
TW	450	Zou et al. (1995) "Structure-function analysis of the p35 subunit of mouse interleukin 12." J. Bio. Chem. 270(11):5864-5871			
1	451	<b>Zuschek et al.</b> (1961) "Immunogenicity of 2 Infectious Bovine Rhinotracheitis Vaccines." <i>J. Am. Vet. Med. Assoc.</i> 139"236-237			
V	452	<b>Zygraich et al.</b> (1974) *In Vivo and In Vitro Properties of a Temperature Sensitive Mutant of Infectious Bovine Rhinotracheitis Virus.* <i>Res. Vet. Sci.</i> 16:328-335			
		·			

JUN 0 5 2002

		(	
Examiner		Date	. 1 1
Signature	T. Wenril	Considered	6/11) /07